fructose-1,6-bisphosphatase


Also found in: Wikipedia.

fructose-1,6-bisphosphatase

/fruc·tose-1,6-bis·phos·pha·tase/ (bis-fos´fah-tās) an enzyme catalyzing part of the route of gluconeogenesis in the liver and kidneys; deficiency causes apnea, hyperventilation, hypoglycemia, ketosis, and lactic acidosis and can be fatal in the neonatal period.
References in periodicals archive ?
Further, the molecular interaction study of the ligands 1, 2 and glibenclamide with various diabetes mellitus related protein targets like glucokinase (PDB ID: 1V4S), fructose-1,6-bisphosphatase 1 (PDB ID: 2JJK) 11-[beta]-hydroxysteroid dehydrogenase (PDB ID: 2BEL) and modeled protein sulfonylurea receptor 1 (SUR1) showed that ligand 1 and 2 possess binding affinity with all protein targets except for 2BEL target protein for which ligand 1 has no interaction.
MB07803 is Metabasis' product candidate for the treatment of type 2 diabetes that acts by inhibiting fructose-1,6-bisphosphatase (FBPase).
ABSTRACT : Fructose-1,6-bisphosphatase (FBP1) is a key regulatory enzyme of gluconeogenesis that catalyzes the hydrolysis of fructose-1,6-bisphosphate to generate fructose-6-phosphate and inorganic phosphate.
Reddy showed that the method accurately predicted the potencies of several inhibitors of fructose-1,6-bisphosphatase, an enzyme that is considered a potential new drug target for type 2 diabetes.
Ligand entered into an option agreement with an undisclosed partner for the clinical development of an undisclosed novel inhibitor of the fructose-1,6-bisphosphatase (FBPase) enzyme for the treatment of type 2 diabetes.
The results showed that fasting blood glucose, PT, APTT, Oxy-LDL, TC, TG, LDL, ALT, AST, ALP, glucose-6-phosphatase, fructose-1,6-bisphosphatase and LPO levels were significantly (p < 0.
ActiveSight plans to add additional kinases, nuclear hormone receptors, and proteases to the Protein Portfolio which already includes human Hsp90 and Fructose-1,6-bisphosphatase.
CHAPTER 4 DISCOVERY OF HETEROCYCLIC PHOSPHONIC ACIDS AS NOVELAMPMIMICS THAT ARE POTENT AND SELECTIVE FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND ELICIT POTENT GLUCOSE-LOWERING EFFECTS IN DIABETIC ANIMALS AND HUMANS
The altered activities of the key enzymes of carbohydrate metabolism such as hexokinase, pyruvate kinase, lactate dehydrogenase, glucose-6-phosphatase, fructose-1,6-bisphosphatase, glucose-6-phosphate dehydrogenase, glycogen synthase and glycogen phosphorylase in liver of diabetic rats were significantly reverted to near normal levels by the administration of tangeretin.
27 /PRNewswire/ -- Fructose-1,6-bisphosphatase (FBPase) is a key regulatory enzyme in the gluconeogenic pathway and a target for the development of novel diabetes therapeutics focused on lowering hepatic glucose production in type 2 diabetics.
We continue to execute on that plan, which is focused on initiating and completing a 12-week Phase 2a proof-of-concept trial on MB07811, our liver-targeted thyroid receptor agonist for hyperlipidemia, and on establishing corporate partnerships for our glucagon antagonist program and for MB07803, our Phase 2 product candidate for type 2 diabetes that targets the enzyme fructose-1,6-bisphosphatase.
Diabetic rats showed decreased activity of hexokinase, and, increased activities of glucose-6-phosphatase, fructose-1,6-bisphosphatase and glucose-6-phosphate dehydrogenase.

Full browser ?